复旦大学生物化学与分子生物学-徐洁杰

徐洁杰，博士，副研究员，博士生导师。2002年获四川大学华西医学中心（原华西医科大学）医学学士学位，2005年获四川大学生命科学学院理学硕士学位，2010年获复旦大学上海医学院医学博士学位，之后在复旦大学基础医学院做生物学博士后研究，2012年博士后出站留校任教，先后入选全国优秀博士学位论文提名奖、复旦大学“卓学计划”、上海市"青年科技启明星"、教育部"新世纪优秀人才"。

徐洁杰副研究员长期致力于肿瘤免疫调节与免疫耐受研究，研究方向为肿瘤免疫逃逸的形成机制。迄今在Gastroenterology、Hepatology、Eur Urol、Nat Commun、Ann Oncol、Clin Cancer Res、Cancer Res、Eur J Cancer、Br J Cancer、Oncoimmunology、Ann Surg、JAMA Surg、Cell Death Differ、Cell Death Dis、J Biol Chem等肿瘤学领域国际权威期刊发表第一作者和通讯作者SCI论文27篇，其中影响因子10以上的论文达6篇，最高影响因子为20.773。多次受邀为Lancet、Lancet Oncol、Hepatology、J Am Soc Nephrol、Theranostics、Mol Cancer等国际知名肿瘤学期刊审稿。

主要研究方向

    肿瘤免疫调节与免疫耐受、肿瘤免疫逃逸的形成机制

主要承担课题

    课题来源                课题编号

    国家自然科学基金   31770851      （面上项目）

    国家自然科学基金   81472227      （面上项目）

    国家自然科学基金   31270863      （面上项目）

    国家科技部             2012ZX10002-012-007 （国家科技重大专项子课题）

    上海市科委             13QA1400300  （上海市青年科技启明星计划） 

    教育部                    NCET-13-0146 （教育部新世纪优秀人才支持计划）

    复旦大学                 EZF101354     （复旦大学卓学计划）

代表性论文列表 (* 为通讯作者)

1、Wang J, Li H, Zhang H, Chen Y, Cao Y, Li R, Lin C, Wei Y, Xiang X, Fang H, Zhang H, Gu Y, Liu X, Zhou R, Liu H, He H, Zhang W*, Shen Z*, Qin J*, Xu J*. Intratumoral IL17-producing cells infiltration correlate with anti-tumor immune contexture and improved response to adjuvant chemotherapy in gastric cancer. Ann Oncol. 2018 in press (共同通讯作者，IF=13.926)

2、Wang J, Liu L, Bai Q, Ou C, Xiong Y, Qu Y, Wang Z, Xia Y, Guo J*, Xu J*. Tumor-infiltrating neutrophils predict therapeutic benefit of tyrosine kinase inhibitors in metastatic renal cell carcinoma. Oncoimmunology. 2018 in press (共同通讯作者，IF=5.503)

3、Fu Q, Xu L, Wang Y, Jiang Q, Liu Z, Zhang J, Zhou Q, Zeng H, Tong S, Qi Y, Hu B, Fu H, Xie H, Zhou L, Chang Y, Zhu Y, Dai B*, Zhang W*, Xu J*. Tumor-associated macrophage-derived IL-23 interlinks kidney cancer glutamine addiction with immune evasion. Eur Urol. 2018 Oct 4. pii: S0302-2838(18)30718-8. doi: 10.1016/j.eururo.2018.09.030. [Epub ahead of print] (共同通讯作者，IF=17.581)

4、Lin Z, Liu L, Xia Y, Chen X, Xiong Y, Qu Y, Wang J, Bai Q, Guo J*, Xu J*. Tumor infiltrating CD19+ B lymphocytes predict prognostic and therapeutic benefits in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors. Oncoimmunology. 2018 Aug 6;7(10): e1477461. (共同通讯作者，IF=5.503)

5、Liu Z, Zhu Y, Xu L, Zhang J, Xie H, Fu H, Zhou Q, Chang Y, Dai B*, Xu J*. Tumor stroma-infiltrating mast cells predict prognosis and adjuvant chemotherapeutic benefits in patients with muscle invasive bladder cancer. Oncoimmunology. 2018 Aug 1;7(9): e1474317. (共同通讯作者，IF=5.503)

6、Fu H, Zhu Y, Wang Y, Liu Z, Zhang J, Fu Q, Dai B, Ye D*, Xu J*. Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle Invasive Bladder Cancer. Clin Cancer Res. 2018 Jul;24(13); 3069–78. (共同通讯作者，IF=10.199)

7、Wu S, He H, Liu H, Cao Y, Li R, Zhang H, Li H, Shen Z*, Qin J*, Xu J*. C-C motif chemokine 22 predicts postoperative prognosis and adjuvant chemotherapeutic benefits in patients with stage II/III gastric cancer. Oncoimmunology. 2018 May 12;7(6):e1433517. (共同通讯作者，IF=5.503)

8、Zhang H, Liu H, Shen Z, Lin C, Wang X, Qin J, Qin X, Xu J*, Sun Y*. Tumor infiltrating neutrophils is prognostic and predictive for postoperative adjuvant chemotherapy benefit in patients with gastric cancer. Ann Surg. 2018 Feb;267(2):311-318. (共同通讯作者，IF=9.203)

9、Cao Y, Liu H, Li H, Lin C, Li R, Wu S, Zhang H, He H*, Zhang W*, Xu J*. Association of O6-Methylguanine-DNA Methyltransferase Protein Expression With Postoperative Prognosis and Adjuvant Chemotherapeutic Benefits Among Patients With Stage II or III Gastric Cancer. JAMA Surg. 2017 Nov 15;152(11):e173120. (共同通讯作者，IF=8.498)

10、Zhu Y, Liu Z, Wang Y, Fu H, Wang Z, Xie H, Zhang J, Li G, Dai B, Xu J*, Ye D*. High CXC chemokine receptor 1 level represents an independent negative prognosticator in non-metastatic clear-cell renal cell carcinoma patients. Oncoimmunology. 2017 Aug 8;6(11):e1359450. (共同通讯作者，IF=5.503)

11、Wang J, Lin C, Li H, Li R, Wu Y, Liu H, Zhang H, He H, Zhang W*, Xu J*. Tumor-infiltrating γδT cells predict prognosis and adjuvant chemotherapeutic benefits in patients with gastric cancer. Oncoimmunology. 2017 Jul 24;6(11):e1353858. (共同通讯作者，IF=5.503)

12、Liu Y, Liu H, Yang L, Wu Q, Liu W, Fu Q, Zhang W, Zhang H, Xu J*, Gu J*. Loss of N-acetylgalactosaminyltransferase-4 orchestrate oncogenic microRNA-9 in hepatocellular carcinoma. J Biol Chem. 2017 Feb 24;292(8):3186-200. (共同通讯作者，IF=4.01)

13、Zhou L, Xu L, Chen L, Fu Q, Liu Z, Chang Y, Lin Z*, Xu J*. Tumor infiltrating neutrophils predict benefit from adjuvant chemotherapy in patients with muscle invasive bladder cancer. Oncoimmunology. 2017 Feb 21;6(4):e1293211. (共同通讯作者，IF=5.503)

14、Fu Q, Chang Y, An H, Fu H, Zhu Y, Xu L, Zhang W*, Xu J*. Prognostic Value of Interleukin-6 and Interleukin-6 Receptor in Organ-Confined Clear-Cell Renal Cell Carcinoma: A 5-Year Conditional Cancer-Specific Survival Analysis. Br J Cancer. 2015 Dec 1;113(11):1581-1589. (共同通讯作者，IF=5.922)

15、Liu W, Liu Y, Liu H, Zhang W, Fu Q, Xu J*, Gu J*. Tumor suppressive function of p21-activated kinase 6 in hepatocellular carcinoma. J Biol Chem. 2015 Nov 20;290(47):28489-501. (共同通讯作者，IF=4.01)

16、Liu H, Liu Y, Liu W, Zhang W, Xu J*. EZH2-mediated loss of miR-622 determines CXCR4 activation in hepatocellular carcinoma. Nat Commun. 2015 Sep 25;6:8494. (通讯作者，IF= 12.353)

17、An H, Xu L, Chang Y, Zhu Y, Yang Y, Chen L, Lin Z*, Xu J*. CXC chemokine receptor 2 is associated with postoperative recurrence and survival of patients with non-metastatic clear-cell renal cell carcinoma. Eur J Cancer. 2015 Sep;51(14):1953-61. (共同通讯作者，IF=7.191)

18、Chang Y, An H, Xu L, Zhu Y, Yang Y, Lin Z*, Xu J*. Systemic inflammation score predicts postoperative prognosis of patients with clear-cell renal cell carcinoma. Br J Cancer. 2015 Aug 11;113(4):626-33. (共同通讯作者，IF=5.922)

19、Zhu Y, Liu H, Xu L, An H, Liu W, Liu Y, Lin Z, Xu J*. p21-activated kinase 1 determines stem-like phenotype and sunitinib resistance via NF-κB/IL-6 activation in renal cell carcinoma. Cell Death Dis. 2015 Feb 12;6:e1637. (通讯作者，IF=5.378)

20、Zhang W, Liu H, Liu W, Liu Y, Xu J*. Polycomb-mediated loss of microRNA let-7c determines inflammatory macrophage polarization via PAK1-dependent NF-κB pathway. Cell Death Differ. 2015 Feb;22(2):287-97. (通讯作者，IF=8.000)

21、Wu Q, Liu HO, Liu YD, Liu WS, Pan D, Zhang WJ, Yang L, Fu Q, Xu JJ*, Gu JX*. Decreased Expression of Hnf4α/miR-122 Axis in Hepatitis B Virus-associated Hepatocellular Carcinoma Enhances Potential Oncogenic GALNT10 Activity. J Biol Chem. 2015 Jan 9;290(2):1170-85. (共同通讯作者，IF=4.01)

22、Zhang H, Wang X, Xu J*, Sun Y*. Notch1 activation is a poor prognostic factor in patients with gastric cancer. Br J Cancer. 2014 Apr 29;110(9):2283-90.  (共同通讯作者，IF=5.922)

23、An H, Xu L, Zhu Y, Lv T, Liu W, Liu Y, Liu H, Chen L*, Xu J*, Lin Z*. High C-X-C chemokine receptor 4 expression is an adverse prognostic factor in patients with clear-cell renal cell carcinoma. Br J Cancer. 2014 Apr 29;110(9):2261-8. (共同通讯作者，IF=5.922)

24、He H, Shen Z, Zhang H, Wang X, Tang Z, Xu J*, Sun Y*. Clinical significance of polypeptide N-acetylgalactosaminyl transferase-5 (GalNAc-T5) expression in patients with gastric cancer. Br J Cancer. 2014 Apr 15;110(8):2021-9. (共同通讯作者，IF=5.922)

25、Xu J, Liu H (co-first author), Chen L, Wang S, Zhou L, Yun X, Sun L, Wen Y*, Gu J*. Hepatitis B virus X protein confers resistance of hepatoma cells to anoikis by up-regulating and activating p21-activated kinase 1. Gastroenterology. 2012 Jul;143(1):199-212.e4. (并列第一作者，IF=20.773)

26、Liu H, Xu J (co-first author), Zhou L, Yun X, Chen L, Wang S, Sun L, Wen Y*, Gu J*. Hepatitis B virus large surface antigen promotes liver carcinogenesis by activating the Src/PI3K/Akt pathway. Cancer Res. 2011 Dec 15;71(24):7547-57. (并列第一作者，IF=9.130)

27、Xu J, Yun X, Jiang J, Wei Y, Wu Y, Zhang W, Liu Y, Wang W, Wen Y*, Gu J*. Hepatitis B virus X protein blunts senescence-like growth arrest of human hepatocellular carcinoma by reducing Notch1 cleavage. Hepatology. 2010 Jul;52(1):142-54. (第一作者，IF=14.079)